Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miles W Carroll

Showing results (11-20 of 144) with videos related to

Pageof 15
Sort By:
Frontiers in Immunology|June 6, 2018
Herd Immunity to Ebolaviruses Is Not a Realistic Target for Current Vaccination StrategiesStuart G Masterson, Leslie Lobel, Miles W Carroll, et al.
Frontiers in Immunology|April 21, 2022
Vaccine-Associated Enhanced Disease and Pathogenic Human CoronavirusesCillian Gartlan, Tom Tipton, Francisco J Salguero, et al.
Cancer Immunology, Immunotherapy : CII|November 29, 2005
Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediatedRichard Harrop, Matthew G Ryan, Kevin A Myers, et al.
Plos One|March 14, 2014
A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse modelKaren R Buttigieg, Stuart D Dowall, Stephen Findlay-Wilson, et al.
Frontiers in Epidemiology|March 8, 2024
Quantifying human-animal contact rates in Malaysian Borneo: Influence of agricultural landscapes on contact with potential zoonotic disease reservoirsHannah Klim, Timothy William, Tock H Chua, et al.
Journal of Proteome Research|October 28, 2016
Elucidation of the Cellular Interactome of Ebola Virus Nucleoprotein and Identification of Therapeutic TargetsIsabel García-Dorival, Weining Wu, Stuart D Armstrong, et al.
Molecular Cancer Therapeutics|December 17, 2002
Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumorsKate Mulryan, Matthew G Ryan, Kevin A Myers, et al.
The Biochemical Journal|May 11, 2002
Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancerAndrew M Woods, Who W Wang, David M Shaw, et al.
Cancer Gene Therapy|October 19, 2002
Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteinsKevin A Myers, Matthew G Ryan, Peter L Stern, et al.
Plos One|June 9, 2016
Protective effects of a Modified Vaccinia Ankara-based vaccine candidate against Crimean-Congo Haemorrhagic Fever virus require both cellular and humoral responsesStuart D Dowall, Victoria A Graham, Emma Rayner, et al.
Pageof 15

Showing results (11-20 of 144) with videos related to

Sort By:
Pageof 15
Frontiers in Immunology|June 6, 2018
Herd Immunity to Ebolaviruses Is Not a Realistic Target for Current Vaccination StrategiesStuart G Masterson, Leslie Lobel, Miles W Carroll, et al.
Frontiers in Immunology|April 21, 2022
Vaccine-Associated Enhanced Disease and Pathogenic Human CoronavirusesCillian Gartlan, Tom Tipton, Francisco J Salguero, et al.
Cancer Immunology, Immunotherapy : CII|November 29, 2005
Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediatedRichard Harrop, Matthew G Ryan, Kevin A Myers, et al.
Plos One|March 14, 2014
A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse modelKaren R Buttigieg, Stuart D Dowall, Stephen Findlay-Wilson, et al.
Frontiers in Epidemiology|March 8, 2024
Quantifying human-animal contact rates in Malaysian Borneo: Influence of agricultural landscapes on contact with potential zoonotic disease reservoirsHannah Klim, Timothy William, Tock H Chua, et al.
Journal of Proteome Research|October 28, 2016
Elucidation of the Cellular Interactome of Ebola Virus Nucleoprotein and Identification of Therapeutic TargetsIsabel García-Dorival, Weining Wu, Stuart D Armstrong, et al.
Molecular Cancer Therapeutics|December 17, 2002
Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumorsKate Mulryan, Matthew G Ryan, Kevin A Myers, et al.
The Biochemical Journal|May 11, 2002
Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancerAndrew M Woods, Who W Wang, David M Shaw, et al.
Cancer Gene Therapy|October 19, 2002
Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteinsKevin A Myers, Matthew G Ryan, Peter L Stern, et al.
Plos One|June 9, 2016
Protective effects of a Modified Vaccinia Ankara-based vaccine candidate against Crimean-Congo Haemorrhagic Fever virus require both cellular and humoral responsesStuart D Dowall, Victoria A Graham, Emma Rayner, et al.
Pageof 15